Tardive Dyskinesia

The inhaled INBRIJA therapy is indicated to treat 'off' episodes in patients taking carbidopa/levodopa.

Tardive dyskinesia made strides in 2018 with new and potential treatments as well as unearthed disease underpinnings.

A more multidisciplinary, collaborative care effort for these patients can result in more active monitoring and productive clinical care.

There were no significant differences among tardive syndrome patients and healthy controls in either resting motor function or active motor function, and both group's symptoms improved with raised intensity.

Most of the patients in the study were taking concomitant antidepressants and/or antipsychotics, and mood disorders remained stable during treatment with valbenazine.

With a recent FDA approval as the first ever therapy for TD, as well as the first ongoing phase 4 clinical trial, valbenazine use is under close watch by clinicians and specialists.

Patients with tardive syndromes treated with transcranial magnetic stimulation had greater improvement in AIMS scores compared to the sham group.

Research with more diverse patient populations is needed to confirm this new discovery.

Tardive dyskinesia due to lithium treatment is still rare, but the antipsyhotic therapy substitute was linked to at least 1 particular patient case.

A study of deep brain stimulation in patients with tardive dyskinesia and dystonia reports promising results.

Patients receiving valbenazine for tardive dyskinesia reported high levels of satisfaction, even after up to 2 years of treatment.

Long-term treatment with valbenazine improved tardive dyskinesia symptoms over 48 weeks.

Antipsychotic dose reductions can increase mental illness and all-cause hospitalizations, but the effects on tardive dyskinesia were unclear.

Recent studies questioned the benefits of second-generation antipsychotics, prompting researchers to reassess the risks of tardive dyskinesia from the use of first- and second-generation antipsychotics.

A recent study investigating the HSPG2 gene in connection with tardive dyskinesia sheds new light on the root causes of the condition.

The FDA’s post-marketing review concludes a five-month speculation which began when CNN reported the Acadia Pharmaceutical antipsychotic therapy was associated with more than 700 deaths of patients with Parkinson disease since June 2016.

Study findings may facilitate new studies on the neural markers of tardive dyskinesia.

Data presented at the2018 World Congress on Parkinson's Disease and Related Disorders indicate that valbenazine is a promising treatment for tardive dyskinesia, while opicapone may be a new effective treatment for Parkinson disease.

Tardive Dyskinesia Assessment Workshop members confirm the AIMS to be a valid measure of TD, but recommends alternative analyses to gauge treatments.

The FDA approved the 2 VMAT-2 drugs for the treatment of tardive dyskinesia in 2017.

A review of tardive dyskinesia epidemiology implicates newer "atypical" antipsychotics as well as older neuroleptics.

The symptoms of tardive dyskinesia and drug-induced parkinsonism can be remarkably similar, but an accurate diagnosis is critical when treatment for one condition may worsen the other.

If done ethically, the genetic database's collaboration with GSK could provide researchers what they really need to improve neurological care: the right patients in the right studies.

Times are tough. Medicine needs a hero.

The long-acting injectable risperidone (Perseris) will provide an alternative to daily oral medication to improve treatment adherence for patients with schizophrenia.

A systematic review and meta-analysis reveals differences between VMAT-2 inhibitors for tardive dyskinesia in absence of head-to-head clinical trials.

Three-quarters of patients who discontinue antipsychotic treatment experience relapse within 12-18 months. However, there are no current clinical guidelines describing treatment continuation or discontinuation beyond 1-2 years.

Researchers measured the VMAT2 inhibitors for clinical effectiveness, cost-effectiveness, and budget impact of these medications.

An analysis of pediatric ICU interactions found that physicians are far more likely to get a beneficial response from families when they show empathy to their emotions.

Sialorrhea is a common symptom in patients with neurological conditions such as Parkinson’s disease, ALS, cerebral palsy, or in patients who have experienced a stroke.